MAPS_2C: MAPS, figure 2C
In raredd/kmdata: A Database of Reconstructed Individual Patient Level Data from Oncology Clinical Trials
MAPS_2C R Documentation
MAPS, figure 2C
Description
Kaplan-Meier digitized data from MAPS, figure 2C (PMID 26719230). A reported sample size of 448 for a primary endpoint of OS in lung cancer.
Usage
MAPS_2C
Format
A data frame of 448 observations and 3 variables:
time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (pc, pcb)
Source
Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly
diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin
Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase
3 trial. Lancet 2016; 387: 1405–14.
Examples
summary(MAPS_2C)
kmplot(MAPS_2C)
raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
| MAPS_2C | R Documentation |
MAPS, figure 2C
Description
Kaplan-Meier digitized data from MAPS, figure 2C (PMID 26719230). A reported sample size of 448 for a primary endpoint of OS in lung cancer.
Usage
MAPS_2C
Format
A data frame of 448 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0: no event, 1: event) |
|
arm | treatment arms (pc, pcb) | |
Source
Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387: 1405–14.
Examples
summary(MAPS_2C)
kmplot(MAPS_2C)
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
Embedding an R snippet on your website
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.